Blog/News
Portland, OR – January 28, 2025 (FORBES) Fans of The Big Lebowski know the movie’s narrator introduces the protagonist as “the man for this time and place.” Like Lebowski, Portland, Oregon-based Eclypsium is seizing its role in the moment, landing a $45M Series…
Read More
November 23, 2023 – Sixty Degree Capital is excited to announce the final close of its third venture capital fund, with $250M earmarked for high-growth companies from Series A to pre-IPO stages across enterprise software and healthcare. Fund III is…
Read More– Plan to initiate the IMAG1NE Phase 1/2 clinical study of TK-8001, a TCR-T cell therapy for MAGE-A1 positive solid tumors, in 2021 August 02, 2021 08:00 ET| Source: T-knife Therapeutics SAN FRANCISCO and BERLIN, Aug. 02, 2021 (GLOBE NEWSWIRE) —…
Read MoreExisting investors NEA, Oak HC/FT and Alta Partners, and new investors, including Endeavor Catalyst, joined the round Funding will accelerate growth, enhance Everside’s technology stack to facilitate predictive, whole-patient care, and support potential M&A opportunities DENVER, July 25, 2022 /PRNewswire/ — Everside Health, LLC, a leading national direct…
Read More— Collaboration Leverages Expertise Across Both Companies, Including Kite’s Global Cell Therapy Leadership and Industry Leading Reliable Manufacturing — SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced…
Read MoreJanuary 09, 2023 02:05 ET| Source: CinCor Pharma IncFollow WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (NASDAQ: CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire…
Read More
HAYWARD, Calif.–(BUSINESS WIRE)–RefleXion Medical, a therapeutic oncology company, today announced the U.S. Food and Drug Administration (FDA) has granted the first marketing clearance for its SCINTIX™ biology-guided radiotherapy, a cutting-edge treatment applicable for early and late-stage cancers. The company will host…
Read MorePrograms target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells January 10, 2023 09:00 AM Eastern Standard Time CAMBRIDGE, Mass. & LEVERKUSEN, Germany–(BUSINESS WIRE)–NextPoint Therapeutics, a biotechnology company developing a new world of precision…
Read More
AUTHOR : STRIVE HEALTH DENVER — May 31, 2023 — Strive Health, a national leader in value-based kidney care, has raised $166 million in Series C funding. This funding round was led by NEA alongside five new investors, including large strategic investor…
Read MoreGAITHERSBURG, Md., April 13, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it raised $115 million in a Series C financing to advance its pipeline of adaptive and controllable cell therapies. The proceeds…
Read More